With its approval, exenatide once weekly has joined exenatide twice daily and liraglutide in the GLP-1 agonist armamentarium available to clinicians. Given their adverse effect profile, as a class ...

Yeztugo showed promising results in clinical trials. One study involving women in Africa reported 100% efficacy, with zero ...

The US Food and Drug Administration (FDA) approved Yeztugo, a long-awaited semi-annual injectable treatment for the prevention of HIV, developed by Gilead Sciences. The approval of Yeztugo marks a ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...

FDA Approves Yeztugo as First Twice-Yearly Injectable HIV Prevention Option in the U.S. Clinical Trials Show Near-Perfect ...

JACKSON, Miss. — The FDA has approved Yeztugo, the world’s first twice-a-year shot to prevent HIV infection, marking a significant advancement in HIV prevention. The new treatment is expected to be a ...

Pablo Barrios scored twice and Atlético Madrid beat the Seattle Sounders 3-1 on Thursday in the Club World Cup.

Pablo Barrios scored twice and Atlético Madrid beat the Seattle Sounders 3-1 on Thursday in the Club World Cup. Giuliano Simeone found Barrios at the top of the penalty box in transition to open ...

WASHINGTON D.C., DC — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it's ...

PrEp has been prescribed as a daily pill or a shot given every two months. This new twice-yearly drug called lenacapavir is now the longest-lasting type of PrEP.

The U.S. has just approved a powerful new weapon in the fight against HIV: a twice-a-year prevention shot called Yeztugo. Made by Gilead Sciences, the injectable treatment slashes the risk of HIV ...

Sax said the twice-a-year shot might appeal to those who aren't willing or able to take a daily pill. "The key is getting people to take (PrEP) and having them reliably do so," Sax said.